New award with mylan pharmaceuticals for fluticasone effective 8-1-21 to 7-31-22 base + 4 one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79721D0037
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 97% complete
IDV ceiling
$366,011,941.10
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

Mylan Pharmaceuticals Inc. was awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs National Acquisition Center on August 1, 2021, with a ceiling value of $366,011,941.10. The contract encompasses the supply of fluticasone inhalers—specifically inhaled corticosteroid/long-acting beta-agonist combination products—to support the VA pharmaceutical prime vendor program, the Bureau of Prisons, and the Indian Health Service. The contract structure includes a one-year base period running from August 1, 2021, through July 31, 2022, with four one-year renewal options, establishing an ultimate completion date of December 31, 2026. The estimated annual usage is approximately 3,050,074 containers distributed across three product line items, with distribution allocated as follows: 10% for line item 1a, 54% for line item 1b, and 36% for line item 1c. This acquisition was conducted as an open competition with no set-aside restrictions, and all responsible sources were eligible to submit proposals in response to the pre-solicitation notice posted on February 8, 2021.

The fluticasone contract award reflects the VA's ongoing requirement for respiratory medications that address chronic obstructive pulmonary disease and asthma management across the federal healthcare system. Mylan, as a manufacturer of pharmaceutical preparations classified under NAICS code 325412, has demonstrated substantial experience supplying specialty pharmaceutical products to federal agencies since 2003, with particular expertise in serving the VA and other federal healthcare programs. The contract incorporates Mylan's subcontracting plan requirements and leverages the established VA pharmaceutical prime vendor distribution network to ensure consistent supply of these critical respiratory medications to veterans and eligible populations served by the VA, Bureau of Prisons, and Indian Health Service throughout the contract term.

Transactions

Action Obligated Date
Add Subcontract Plan P00011 · This modification is issued to incorporate mylan's subcontracting plan into contract 36E79721D0037. $0
Exercise an Option P00010 · This modification is issued to exercise the fourth option year for inhaled corticosteroid/long-acting beta-agonist inhalers $0
Add Subcontract Plan P00009 · This unilateral modification is issued to incorporate the approved commercial company wide small business subcontracting plan. $0
Exercise an Option P00008 · This modification is issued to exercise the third option year for inhaled corticosteroid/long-acting beta-agonist inhalers. $0
Supplemental Agreement for work within scope P00007 · This modification is issued to update the terms of the CRF payment remittal and submission of quarterly sales reports. $0
Add Subcontract Plan P00006 · This modification is being issued to incorporate mylan institutional LLC subcontracting plan $0
Exercise an Option P00005 · Exercise the second option year for inhaled corticosteroid/long-acting beta-agonist $0
Other Administrative Action P00004 · Title II of the drug quality and security act (dqsa), known as the dscsa, applies to all drug products, with the exception of those listed on the dscsa… $0
Add Subcontract Plan P00003 · This modification is issued to incorporate mylan institutional LLC subcontracting plan $0
Exercise an Option P00002 · This modification is issued to exercise the first option year for inhaled corticosteroid/long-acting beta-agonist $0
Add Subcontract Plan P00001 · Incorporate mylan institutional LLC subcontracting plan $0
Original award $0
Show all 12

Quick answers

Who was awarded contract 36E79721D0037?

36E79721D0037 was awarded to Mylan Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on August 1, 2021.

How much is contract 36E79721D0037 worth?

36E79721D0037's own ceiling is $366,011,941.

Who can order from contract 36E79721D0037?

36E79721D0037 is a single award indefinite delivery contract.

Was contract 36E79721D0037 competed?

The extent of competition for 36E79721D0037 was full and open competition. The government received 3 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login